EMA Authorised: Dimethyl fumarate Mylan (dimethyl fumarate) — Mylan Ireland Limited

View source ↗

Summary

EMA authorised Dimethyl fumarate Mylan for the treatment of multiple sclerosis. The marketing authorization holder is Mylan Ireland Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Dimethyl fumarate Mylan (dimethyl fumarate)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Mylan Ireland Limited. Decision date: 12/05/2025